News | May 01, 2013

Data From WEARIT-II Trial of Wearable Cardioverter Defibrillator to Be Presented at Heart Rhythm 2013

Zoll WEARIT-II Trial Results Heart Rhythm Society Annual Scientific Session

May 1, 2013 — Zoll Medical said results from the prospective registry and follow-up of Patients Using the Wearable Defibrillator (WEARIT-II) trial will be presented in a late-breaking clinical trial presentation at Heart Rhythm 2013. The session will be presented during the Heart Rhythm Society’s 34th Annual Scientific Sessions, Friday, May 10, 1:30-3 p.m., session number SP22.

The 18-month results from WEARIT-II will be presented by Ilan Goldenberg, M.D., (principal investigator) University of Rochester Medical Center. WEARIT-II is a prospective, observational study designed to evaluate high cardiac risk patients’ clinical information, arrhythmias and treatment findings during wearable defibrillator use and subsequent one-year clinical course, including survival.

“As an investigator in the original WEARIT/BIROAD clinical trial and the co-principal investigator for the WEARIT-II Registry, it is rewarding to see that these data will be shared as part of the Late-Breaking Clinical Trial presentations at Heart Rhythm. The LifeVest plays an important role in the continuum of care for patients at high risk from sudden cardiac arrest,” said Arthur J. Moss, M.D., University of Rochester Medical Center. “The LifeVest allows physicians to protect patients during their period of highest risk early after an acute cardiac event such as a myocardial infarction or newly diagnosed nonischemic cardiomyopathy, when other therapies are not appropriate due to the patient’s changing condition and the potential for cardiac recovery.”

“WEARIT-II is the first multi-national registry of LifeVest usage and is currently enrolling patients in the United States, Europe and Israel. We look forward to this presentation of the 18-month U.S. results,” said Marshal Linder, president of Zoll LifeVest. “These data will add to our understanding of the real-world treatment approaches and outcomes from physicians’ utilization of wearable defibrillators.”

The LifeVest Wearable Defibrillator, along with sudden cardiac arrest (SCA) education and screening tools, will be on display in Booth #539 at Heart Rhythm 2013 May 8 to 11 at the Colorado Convention Center in Denver.

For more information: www.zoll.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init